Hisun Pharmaceutical announced that it recently received the Drug Registration Certificate for Letermovir tablets approved and issued by the National Medical Products Administration. The drug is indicated for cytomegalovirus seropositive adult and pediatric patients undergoing allogeneic hematopoietic stem cell transplantation, for the prevention of cytomegalovirus infection and cytomegalovirus disease. The company's Letermovir tablets were approved as a Category 4 chemical drug, which is deemed to have passed the consistency evaluation.
Zhejiang Hisun Pharmaceutical Co LtdObtained drug registration certificate for Letermovir tablets from NMPA, enabling market entry.